Armie Margaret Lee is a reporter covering private equity. Previously, she was at InvestmentWires, an online media company that focuses on the mutual fund and 401(k) industries. She has also covered real estate and banking for Miami Today and technology for Manila Times in the Philippines.
Recent Articles By The Author
UnitedHealth Shares Rise After Q3 Beat, Raised Guidance
The Minnetonka, Minn.-based healthcare giant released third-quarter numbers that exceeded analysts' expectations.
CVS-Aetna Deal Gets Conditional Approval from DOJ
The Justice Department is requiring the companies to divest Aetna's Medicare Part D prescription drug business.
Former Apple CEO John Sculley Sees Amazon Playing a Key Role in Healthcare
Sculley also said the healthcare initiative formed by Amazon, Berkshire Hathaway and JPMorgan will set a new high-water mark in the healthcare sector.
Teva Shares Pop as FDA Approves Its Migraine Drug
Ajovy is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the FDA to prevent migraines.
Amazon-Berkshire-JPM Health Venture Makes 'Bold Statement' With COO Hire
Amazon, Berkshire Hathaway and JPMorgan Chase tap Comcast alum Jack Stoddard for the No. 2 post at their healthcare initiative.
Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition
The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.
Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside
A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.
Teva Notches Win With FDA Approval of Generic EpiPen
The regulatory agency has authorized the sale of the drugmaker's generic version of Mylan's EpiPen.
Loncar China BioPharma ETF Makes Nasdaq Debut
The launch comes as China's biotech industry is undergoing a transformation, index developer Brad Loncar noted in an interview.
Buffett Ups Stake in Teva
Warren Buffett's Berkshire Hathaway increases its stake in the drugmaker to 43.2 million shares from 40.5 million shares at the end of March.